+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multi-target MET TKIs Market - Global Forecast 2026-2032- Product Image
Multi-target MET TKIs Market - Global Forecast 2026-2032- Product Image
Sale

Multi-target MET TKIs Market - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6129662
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Multi-target MET TKIs Market is projected to reach USD 2.40 Billion in 2026. It is expected to continue growing at a CAGR of 9.74%, reaching USD 4.18 Billion by 2032.

Multi-target MET TKIs: Executive Overview

Multi-target MET tyrosine kinase inhibitors (TKIs) are small-molecule therapies designed to inhibit MET alongside additional kinases implicated in tumor growth, invasion, angiogenesis, or treatment resistance. Their clinical relevance is shaped by the biological diversity of MET alterations, including amplification, overexpression, exon 14 skipping, and pathway activation. Evaluation therefore depends on biomarker selection, tumor type, prior treatment, safety profile, and the availability of confirmatory clinical evidence.

Biomarker Precision Is Reshaping Multi-target MET TKI Development

The landscape is shifting from broad pathway inhibition toward biomarker-defined treatment strategies. Diagnostic testing for MET exon 14 skipping, amplification, and other activation patterns is becoming central to patient identification, while trial designs increasingly distinguish molecularly selected populations from tumors with nonspecific MET expression. At the same time, developers must balance broader kinase coverage against off-target toxicity, drug-drug interactions, and the potential for overlapping adverse events. Combination strategies, sequential treatment, and resistance management are also gaining importance as clinicians seek to extend disease control beyond initial response.

Artificial Intelligence Strengthens Biomarker and Treatment Decisions

Artificial intelligence can support multi-target MET TKI development by integrating genomic, transcriptomic, imaging, and clinical data to identify response-associated patterns. Machine-learning tools may improve interpretation of complex MET alterations, help prioritize patients for testing, and identify combinations that address bypass signaling or acquired resistance. In clinical practice, AI-assisted radiology and pathology could complement molecular diagnostics, but implementation requires representative datasets, external validation, transparent performance measures, and safeguards against bias. AI should augment-not replace-clinician judgment and prospective evidence.

Regional Insights: Access and Precision Oncology Capacity Differ

North America benefits from established molecular-diagnostic infrastructure, specialist oncology networks, and active precision-medicine research, although reimbursement and testing access remain important considerations. Europe combines sophisticated clinical research with country-level variation in regulatory implementation, health technology assessment, and diagnostic availability. Asia-Pacific includes advanced oncology systems in Japan, South Korea, and Australia alongside rapidly expanding capabilities in China and India, creating heterogeneous access conditions. Latin America faces uneven availability of biomarker testing and targeted medicines, with Brazil and Mexico serving as important reference markets. In the Middle East, GCC states are strengthening specialist-care capacity, while broader access varies across neighboring systems. Africa continues to face major constraints in molecular diagnostics, specialist oncology services, and treatment affordability, making partnerships and decentralized testing especially relevant.

Group Insights: Policy Blocs Influence Diagnostics and Access

ASEAN markets are characterized by varied regulatory pathways, healthcare financing systems, and diagnostic maturity, making regional coordination valuable for testing standards and evidence generation. BRICS countries combine substantial patient populations with distinct regulatory, manufacturing, and reimbursement environments; local clinical evidence and supply resilience are important priorities. The European Union benefits from coordinated scientific and regulatory structures, but national reimbursement decisions and diagnostic pathways still differ. G7 members generally possess advanced research, pathology, and oncology capabilities, while facing demanding evidence and affordability expectations. GCC countries are investing in specialized healthcare and centralized procurement, creating opportunities for coordinated adoption. NATO members span diverse health systems, so multinational research, preparedness, and supply-chain collaboration may support more consistent access.

Country Insights: National Systems Shape MET TKI Adoption

The United States and Canada have strong oncology research ecosystems and molecular-testing capabilities, with access influenced by payer evidence requirements and clinical guidelines. In Europe, Germany, France, Italy, Spain, and the United Kingdom differ in health technology assessment, procurement, and regional implementation despite substantial clinical expertise. China is expanding precision-oncology infrastructure and domestic innovation, while Japan and South Korea maintain advanced diagnostic and specialist-care systems. Australia combines strong research capacity with geographically dispersed care delivery. India is broadening access to oncology services and diagnostics, but affordability and infrastructure remain central issues. Brazil and Mexico are developing targeted-therapy capacity amid public-private system differences. Russia’s access environment is shaped by regulatory, procurement, and supply considerations. Across all listed countries, reliable MET testing, multidisciplinary interpretation, and post-market evidence are critical to appropriate use.

Priorities for Leaders: Link Evidence, Diagnostics, and Access

Industry leaders should align development programs with clearly defined MET biomarkers and prespecified response criteria, while reporting outcomes separately for biologically distinct patient groups. Companion-diagnostic strategies should be developed early, validated across laboratories, and supported by practical testing pathways. Safety management must account for the full kinase-inhibition profile, particularly when treatment is combined with other anticancer agents. Leaders should invest in resistance research, real-world evidence, and transparent data-sharing to clarify sequencing and combination use. Regional access plans should address reimbursement, clinician education, sample logistics, and equitable testing. Responsible AI adoption requires validated tools, human oversight, cybersecurity, and ongoing monitoring for performance differences across populations.

Methodology: Structured Synthesis of Clinical and Health-System Evidence

This executive summary uses a structured qualitative framework for multi-target MET TKIs. The approach considers mechanism of action, MET biomarker biology, clinical-development priorities, diagnostic requirements, safety considerations, resistance, regional healthcare capacity, policy-group characteristics, and country-level access factors. Insights are synthesized from established oncology and pharmacology principles and are framed without market estimates, market shares, forecasts, or company-specific claims. Because healthcare systems and evidence evolve, conclusions should be tested against current clinical guidelines, regulatory decisions, peer-reviewed studies, and locally applicable reimbursement policies before operational use.

Conclusion: Precision, Safety, and Equitable Implementation Define Progress

Multi-target MET TKIs occupy an important position at the intersection of targeted oncology, biomarker-driven care, and resistance management. Their value will depend less on kinase breadth alone than on matching the right inhibitor to the right molecular context, confirming benefit through rigorous evidence, and managing toxicity across treatment sequences. Regional and national differences in diagnostics, financing, and specialist capacity will strongly influence implementation. Sustainable progress requires coordinated drug-diagnostic development, credible clinical data, responsible use of AI, and access strategies that extend precision oncology beyond well-resourced centers.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Multi-target MET TKIs Market, by Indication
7.1. Introduction
7.2. Gastric Cancer
7.2.1. First Line
7.2.2. Second Line
7.2.3. Third Line And Beyond
7.3. Non Small Cell Lung Cancer
7.3.1. First Line
7.3.2. Second Line
7.3.3. Third Line And Beyond
7.4. Renal Cell Carcinoma
7.4.1. First Line
7.4.2. Second Line
7.4.3. Third Line And Beyond
8. Multi-target MET TKIs Market, by Line Of Therapy
8.1. Introduction
8.2. First Line
8.3. Second Line
8.4. Third Line And Beyond
9. Multi-target MET TKIs Market, by Formulation
9.1. Introduction
9.2. Capsule
9.3. Tablet
10. Multi-target MET TKIs Market, by Patient Age Group
10.1. Introduction
10.2. Adult
10.3. Elderly
11. Multi-target MET TKIs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Retail Pharmacy
11.4. Specialty Pharmacy
12. Multi-target MET TKIs Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Multi-target MET TKIs Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Multi-target MET TKIs Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Amgen Inc
16.2. Astellas Pharma Inc
16.3. AstraZeneca PLC
16.4. Bayer AG
16.5. Boehringer Ingelheim International GmbH
16.6. Bristol-Myers Squibb Company
16.7. Daiichi Sankyo Company, Limited
16.8. Eli Lilly and Company
16.9. Exelixis, Inc
16.10. Genentech, Inc
16.11. GSK plc
16.12. Incyte Corporation
16.13. Ipsen Pharma SAS
16.14. Janssen Pharmaceuticals, Inc
16.15. Merck & Co., Inc
16.16. Novartis AG
16.17. Otsuka Pharmaceutical Co., Ltd
16.18. Pfizer Inc
16.19. Roche Holding AG
16.20. Sanofi S.A.
16.21. Seattle Genetics, Inc
16.22. Takeda Pharmaceutical Company Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Multi-target MET TKIs Market, Years Considered for the Study
FIGURE 2. Global Multi-target MET TKIs Market, Research Design
FIGURE 3. Global Multi-target MET TKIs Market, Research Framework
FIGURE 4. Global Multi-target MET TKIs Market, Data Triangulation
FIGURE 5. Global Multi-target MET TKIs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Multi-target MET TKIs Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global Multi-target MET TKIs Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Multi-target MET TKIs Market Size, by Line Of Therapy, 2025 vs 2032 (%)
FIGURE 9. Global Multi-target MET TKIs Market Size, by Line Of Therapy, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Multi-target MET TKIs Market Size, by Formulation, 2025 vs 2032 (%)
FIGURE 11. Global Multi-target MET TKIs Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Multi-target MET TKIs Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 13. Global Multi-target MET TKIs Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Multi-target MET TKIs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Multi-target MET TKIs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Multi-target MET TKIs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Multi-target MET TKIs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Multi-target MET TKIs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Multi-target MET TKIs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Multi-target MET TKIs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Multi-target MET TKIs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Multi-target MET TKIs Market Segmentation & Coverage
TABLE 2. Global Multi-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Gastric Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Gastric Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Gastric Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global First Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global First Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global First Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Third Line And Beyond Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Third Line And Beyond Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Third Line And Beyond Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Non Small Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Non Small Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Non Small Cell Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global First Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global First Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global First Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Third Line And Beyond Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Third Line And Beyond Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Third Line And Beyond Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Renal Cell Carcinoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Renal Cell Carcinoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Renal Cell Carcinoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global First Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global First Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global First Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Third Line And Beyond Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Third Line And Beyond Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Third Line And Beyond Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 41. Global First Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global First Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global First Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Third Line And Beyond Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Third Line And Beyond Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Third Line And Beyond Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 51. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 58. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Elderly Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Elderly Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Elderly Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 65. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Specialty Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Specialty Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Specialty Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Multi-target MET TKIs Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Multi-target MET TKIs Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 79. Asia-Pacific Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 80. Asia-Pacific Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 81. Asia-Pacific Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 82. Asia-Pacific Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 83. Asia-Pacific Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 84. North America Multi-target MET TKIs Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. North America Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 86. North America Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 87. North America Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 88. North America Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 89. North America Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 90. North America Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 91. North America Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 92. North America Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 93. Latin America Multi-target MET TKIs Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Latin America Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 95. Latin America Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 96. Latin America Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 97. Latin America Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 98. Latin America Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 99. Latin America Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 100. Latin America Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 101. Latin America Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 102. Europe Multi-target MET TKIs Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Europe Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 104. Europe Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 105. Europe Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 106. Europe Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 107. Europe Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 108. Europe Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 109. Europe Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 110. Europe Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 111. Middle East Multi-target MET TKIs Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Middle East Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 113. Middle East Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 114. Middle East Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 115. Middle East Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 116. Middle East Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 117. Middle East Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 118. Middle East Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 119. Middle East Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 120. Africa Multi-target MET TKIs Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. Africa Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 122. Africa Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 123. Africa Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 124. Africa Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 125. Africa Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 126. Africa Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 127. Africa Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 128. Africa Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 129. Global Multi-target MET TKIs Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. ASEAN Multi-target MET TKIs Market Size, by Group, 2017-2032 (USD Million)
TABLE 131. ASEAN Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 132. ASEAN Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 133. ASEAN Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 134. ASEAN Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 135. ASEAN Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 136. ASEAN Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 137. ASEAN Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 138. ASEAN Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 139. GCC Multi-target MET TKIs Market Size, by Group, 2017-2032 (USD Million)
TABLE 140. GCC Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 141. GCC Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 142. GCC Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 143. GCC Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 144. GCC Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 145. GCC Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 146. GCC Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 147. GCC Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 148. European Union Multi-target MET TKIs Market Size, by Group, 2017-2032 (USD Million)
TABLE 149. European Union Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 150. European Union Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 151. European Union Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 152. European Union Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 153. European Union Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 154. European Union Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 155. European Union Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 156. European Union Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 157. BRICS Multi-target MET TKIs Market Size, by Group, 2017-2032 (USD Million)
TABLE 158. BRICS Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 159. BRICS Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 160. BRICS Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 161. BRICS Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 162. BRICS Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 163. BRICS Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 164. BRICS Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 165. BRICS Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 166. G7 Multi-target MET TKIs Market Size, by Group, 2017-2032 (USD Million)
TABLE 167. G7 Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 168. G7 Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 169. G7 Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 170. G7 Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 171. G7 Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 172. G7 Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 173. G7 Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 174. G7 Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 175. NATO Multi-target MET TKIs Market Size, by Group, 2017-2032 (USD Million)
TABLE 176. NATO Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 177. NATO Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 178. NATO Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 179. NATO Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 180. NATO Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 181. NATO Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 182. NATO Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 183. NATO Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 184. Global Multi-target MET TKIs Market Size, by Country, 2017-2032 (USD Million)
TABLE 185. United States Multi-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 186. United States Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 187. United States Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 188. United States Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 189. United States Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 190. United States Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 191. United States Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 192. United States Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 193. United States Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 194. Canada Multi-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 195. Canada Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 196. Canada Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 197. Canada Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 198. Canada Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 199. Canada Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 200. Canada Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 201. Canada Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 202. Canada Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 203. Mexico Multi-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 204. Mexico Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 205. Mexico Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 206. Mexico Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 207. Mexico Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 208. Mexico Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 209. Mexico Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 210. Mexico Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 211. Mexico Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 212. Brazil Multi-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 213. Brazil Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 214. Brazil Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 215. Brazil Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 216. Brazil Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 217. Brazil Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 218. Brazil Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 219. Brazil Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 220. Brazil Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 221. United Kingdom Multi-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 222. United Kingdom Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 223. United Kingdom Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 224. United Kingdom Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 225. United Kingdom Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 226. United Kingdom Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 227. United Kingdom Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 228. United Kingdom Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 229. United Kingdom Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 230. Germany Multi-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 231. Germany Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 232. Germany Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 233. Germany Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 234. Germany Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 235. Germany Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 236. Germany Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 237. Germany Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 238. Germany Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 239. France Multi-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 240. France Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 241. France Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 242. France Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 243. France Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 244. France Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 245. France Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 246. France Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 247. France Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 248. Russia Multi-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 249. Russia Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 250. Russia Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 251. Russia Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 252. Russia Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 253. Russia Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 254. Russia Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 255. Russia Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 256. Russia Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 257. Italy Multi-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 258. Italy Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 259. Italy Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 260. Italy Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 261. Italy Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 262. Italy Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 263. Italy Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 264. Italy Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 265. Italy Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 266. Spain Multi-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 267. Spain Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 268. Spain Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 269. Spain Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 270. Spain Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 271. Spain Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 272. Spain Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 273. Spain Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 274. Spain Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 275. China Multi-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 276. China Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 277. China Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 278. China Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 279. China Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 280. China Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 281. China Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 282. China Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 283. China Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 284. India Multi-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 285. India Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 286. India Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 287. India Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 288. India Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 289. India Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 290. India Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 291. India Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 292. India Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 293. Japan Multi-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 294. Japan Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 295. Japan Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 296. Japan Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 297. Japan Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 298. Japan Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 299. Japan Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 300. Japan Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 301. Japan Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 302. Australia Multi-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 303. Australia Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 304. Australia Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 305. Australia Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 306. Australia Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 307. Australia Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 308. Australia Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 309. Australia Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 310. Australia Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 311. South Korea Multi-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 312. South Korea Multi-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 313. South Korea Multi-target MET TKIs Market Size, by Gastric Cancer, 2017-2032 (USD Million)
TABLE 314. South Korea Multi-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 315. South Korea Multi-target MET TKIs Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 316. South Korea Multi-target MET TKIs Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 317. South Korea Multi-target MET TKIs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 318. South Korea Multi-target MET TKIs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 319. South Korea Multi-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 320. Global Multi-target MET TKIs Market Share, by Key Player, 2025
TABLE 321. Global Multi-target MET TKIs Market, Key Experts

Companies Mentioned

  • Amgen Inc
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol‑Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Exelixis, Inc
  • Genentech, Inc
  • GSK plc
  • Incyte Corporation
  • Ipsen Pharma SAS
  • Janssen Pharmaceuticals, Inc
  • Merck & Co., Inc
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd
  • Pfizer Inc
  • Roche Holding AG
  • Sanofi S.A.
  • Seattle Genetics, Inc
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

Single-target MET TKIs Market - Global Forecast 2026-2032 - Product Image

Single-target MET TKIs Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
MET TKIs Market - Global Forecast 2026-2032 - Product Image

MET TKIs Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Hepatocellular Carcinoma Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology - Product Image

Hepatocellular Carcinoma Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology

  • Report
  • 98 Pages
  • Global
From
Gastrointestinal Stromal Tumor (GIST) - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Gastrointestinal Stromal Tumor (GIST) - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Bone Metastasis in Solid Tumors - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Bone Metastasis in Solid Tumors - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.